Showing results (111-120 of 152) with videos related to
Sort By:
Pageof 16
Epidemiology and Infection|February 3, 2016
Whole genome sequencing reveals extensive community-level transmission of group A Streptococcus in remote communitiesA C Bowen, T Harris, D C Holt, et al.Archives of Physical Medicine and Rehabilitation|November 2, 2001
Paraplegia secondary to Burkholderia pseudomallei myelitis: a case reportM J Haran, A W Jenney, R J Keenan, et al.Epidemiology and Infection|October 12, 2004
Preliminary report on the northern Australian melioidosis environmental surveillance projectT J J Inglis, N F Foster, D Gal, et al.The Journal of Hospital Infection|January 22, 2013
Community-associated meticillin-resistant Staphylococcus aureus carriage in hospitalized patients in tropical northern AustraliaL Brennan, R A Lilliebridge, A C Cheng, et al.The Southeast Asian Journal of Tropical Medicine and Public Health|April 14, 2006
Seroprevalence of Burkholderia pseudomallei in East Timorese refugees: implications for healthcare in East TimorP K Armstrong, N M Anstey, P M Kelly, et al.Australian and New Zealand Journal of Medicine|December 16, 1998
Australian encephalitis in the Northern Territory: clinical and epidemiological features, 1987-1996J N Burrow, P I Whelan, C J Kilburn, et al.Journal of Clinical Microbiology|January 5, 2000
Distribution and antigenicity of fibronectin binding proteins (SfbI and SfbII) of Streptococcus pyogenes clinical isolates from the northern territory, AustraliaA M Goodfellow, M Hibble, S R Talay, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 28, 2009
High-resolution melting analysis of the spa locus reveals significant diversity within sequence type 93 methicillin-resistant Staphylococcus aureus from northern AustraliaS Y C Tong, R A Lilliebridge, D C Holt, et al.Vaccine|May 5, 2011
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 monthsF M Russell, A Balloch, P V Licciardi, et al.The New England Journal of Medicine|September 22, 1988
Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind studyT B Nutman, K D Miller, M Mulligan, et al.Pageof 16